Featured PodcastPodcast Highlights

New Developments in Tetracycline-Class Antibiotics

By December 21, 2020March 18th, 2021No Comments

JDD Multimedia

JDD Podcast

Listen Now

How to Listen

New Developments in Tetracycline-class Antibiotics

Dr. Christopher Bunick & Dr. Adam Friedman

 

Tetracycline antibiotics are like the Snickers of dermatology. Instead of “Hungry? Grab a Snickers,” “Acne? Grab a tetracycline…” for months even though this goes against clinical guidelines and concerns regarding antimicrobial resistance (woof, thats a mouthful for a slogan). Like a Snickers, they fulfill a need, they’re good for a whole lot, but too much, not so good. We have seen some evolution in maximizing the clinical benefits of our therapeutic Snickers, such as subantimicrobial dosing, but more innovation is needed to get the most anti-inflammatory bang for our buck. Enter the concept of narrow spectrum antibiotics and sarecycline.

 Join host Dr. Adam Friedman on an investigative journey detailing how antibiotic structure and function can meet to yield novel properties with Dr. Chris Bunick, Associate Professor of Dermatology at Yale School of Medicine and captain of crystallography and cryo-electron microscopy. Hear first hand how a simple idea morphed into a groundbreaking program. Complete your understanding of how antibiotics can be anti-inflammatory. Love the new narrow spectrum lexicon (or try at least).

Listen Now
This enduring activity is supported by an independent medical education grant provided by Almirall, LLC.
Learning Objectives
Upon completion of this podcast, learners should be able to:
  • Summarize the mechanism of action of tetracycline antibiotics and their role in acne
  • Define narrow spectrum antibiotic, and understand the clinical translation.

Disclosures

 

Adam Friedman, MD, FAAD – Grant/Research: Aclaris, CPN, Almirall. Consultant: SanovaWorks, Oakstone Institute, L’oreal, La Roche Posay, Galderma, Aveeno, Valeant, Microcures, Biogen, Pfizer, G&W Laboratories, Novartis, Occulus, Intraderm, Encore, Exeltis, Menlo, Lilly, Aclaris, Dermira, Berg, Allergan, Zylo Therapeutics, Hoth. Speakers’ Bureau: Regeneron, Dermira, Janssen, AbbVie. Major Stock Shareholder: Zylo, Minorcures.
Christopher Bunick, MD, PhD – Grant/Research: Almirall, Consultant: Almirall, Speakers’ Bureau: Almirall

You May Also Like

Formulation Foundations: A Peak Behind the Development Curtain

| Dermatology Podcast Archives, Featured Podcast, JDD Highlights, Podcast Highlights | No Comments
iTunes TuneIn Spotify Dr. David Osborne Finding the right formulation is not always a fun endeavor for the practitioner or patient, and can be the make or break for patient…

Reface the Chase: Paradigm shifts in the AD Management Strategy Mentality

| Dermatology Podcast Archives, Featured Podcast, JDD Highlights, Podcast Highlights | No Comments
iTunes TuneIn Spotify Dr. Raj Chovatiya Who doesn't love a good game of "Whack a Mole?" Anyone? Just as you try to stay ahead of those furry, taunting, smiling devils…

Diving into Dyspigmentation: Discoloration Details and Future Directions

| Dermatology Podcast Archives, Featured Podcast, JDD Highlights, Podcast Highlights | No Comments
iTunes TuneIn Spotify Dr. Andrew Alexis Dyspigmentation is defeating....for the patient and the practitioner as it is often a secondary feature of chronic inflammatory skin diseases and often a greater…

Leave a Reply